Brookfield Business Corporation heads into its September-quarter report with a story that still looks sturdier on paper than in the share price. Management spent the last call highlighting asset sales, buybacks and steady same-store growth, yet the stock has slid nearly 8% since then while the S&P 500 gained about 3%. That gap suggests the market is focused less on the compounding narrative and more on two problems that surfaced or worsened last quarter: rising claims at Canadian mortgage insurer Sajan and mounting credit stress at CDK. This report is the first real chance to see whether those issues are contained or spreading.

The Street is looking for earnings of $1.25 per share, a modest step up from the $1.21 reported last quarter, when revenue came in around $6.5 billion. Management did not issue formal guidance or raise its targets last time, instead reaffirming its $2 billion, 24-month capital recycling goal and its 15% to 20% return framework. With no explicit outlook to anchor against, the consensus implies only incremental sequential improvement, which seems a reasonable bar given that headline adjusted EBITDA was essentially flat year over year at $587 million, held back by lower ownership stakes even as same-store EBITDA grew roughly 5% to 6% across industrial, business services and infrastructure.

Sajan is the swing factor most likely to move sentiment. Its loss ratio has climbed from a historical level near 5% to 12% and then 17% in consecutive quarters, with reserve strengthening accounting for about a third of the latest figure. Management has steered toward a normalized range of 15% to 25% as falling Canadian home prices reduce cure rates. A reading that stabilizes in the lower half of that band, with less reserve building, would support the idea that the business is simply normalizing. Another sharp jump toward the top of the range would suggest the guidepost itself is drifting. CDK is the other overhang. Its debt has traded at distressed levels, a rating agency placed it on negative watch, and there have been reports of lender talks, even as management insisted operations remain stable. Investors should want evidence of churn holding steady and a clearer path on the capital structure rather than further reassurance alone.

The positive side of the ledger needs to keep delivering. Proceeds of $1.2 billion year to date already exceed half the recycling target, helped by the roughly $650 million Multiplex sale, and corporate liquidity rose to $2.8 billion. Buybacks have topped $300 million at around half of net asset value, with another $150 million allocated. Progress on closing Multiplex, deploying capital into the newly announced World Freight Company and Gregg Distributors deals, and continued debt paydown at Clarios, which retired $500 million last quarter, would reinforce the case that value is being crystallized. In infrastructure services, a rebound from the $96 million EBITDA print, which was dented by a lottery joint venture contract penalty and heavier investment spending, would show that weakness was a one-off. Soft Dexco end markets, with recovery pushed into next year, limit near-term upside there.

Positioning is skeptical. Sentiment remains about 61% bearish, virtually unchanged from the prior quarter, and the stock at $27.83 sits well below its 200-day moving average of $31.38. It trades in the lower half of its post-earnings range of $24.80 to $31.64, a band that has shifted noticeably below the prior quarter's $28.92 to $34.73. That reset lowers the bar somewhat, but it also signals that the market wants proof rather than promises.

Ultimately, the report hinges on whether Sajan and CDK prove to be isolated, manageable blemishes on a portfolio that is otherwise compounding and recycling capital at a healthy clip. If claims level off and CDK avoids further deterioration, the steep discount to asset value looks increasingly hard to justify. If either worsens, the buyback and asset sale story may not be enough to offset it.